San Diego-dependent Viking Therapeutics marked by itself as a significant competitor in the weight loss drug market in February immediately after revealing promising details from a mid-stage trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when offered as a weekly injection As well as in Marc